MyMD Pharmaceuticals, Inc. MYMD
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 4.31M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- 0.00
- Beta
- 2.69
- Short ratio
- 2.71
- Inst. own
- 6.62%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 15, 2024
- 50-d avg
- 1.92
- 200-d avg
- 4.23
- 1y target
- 0.00
Key statistics
- Market cap
- 4.31M
- Enterprise value
- 3.36M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.40
- EPS (TTM)
- -9.27
- Beta
- 2.69
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.93M
- Total cash
- 1.74M
- Total debt
- 35.98K
- Return on equity
- -101.35%
- Shares outstanding
- 2.37M
- Short % of float
- 14.70%
- 50-day average
- 1.92
- 200-day average
- 4.23
Analyst view
Consensus: none
Next earnings
May 15, 2024
Expected May 15, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 31, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mymd.com
News
- TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
- MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer
- PharmaCyte Biotech Makes $7M Investment In MyMD Pharmaceuticals; Investment In Life Sciences Solidifies Previously Announced Strategy To Utilize Significant Cash Position To Create Additional Stockholder Value
- MyMD Pharmaceuticals Secures Strategic Investments
- PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
- Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
- MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
- MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
- 12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on MYMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAPMAN CHRISTOPHER C JR | President | Stock Award(Grant) | Apr 15, 2021 | 96,475 |
| GORMALLY JOHN J | Chief Executive Officer | Stock Award(Grant) | Oct 16, 2017 | 180,000 |
| HUDSON BAY CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 27, 2020 | 0 |
| HUDSON BAY CAPITAL MANAGEMENT. L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 27, 2020 | 0 |
| RIVARD PAUL | Officer | Purchase | Aug 23, 2023 | 400,000 |
| SCHREIBER CHRISTOPHER C | Director | Conversion of Exercise of derivative security | Apr 15, 2021 | 88,238 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.25% | 1,458,295 | 2.19M | Jun 29, 2023 |
| Mirae Asset Global Investments Co., Ltd. | 2.63% | 1,183,616 | 1.78M | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.63% | 282,250 | 423.38K | Jun 29, 2023 |
| Blackrock Inc. | 0.47% | 210,965 | 316.45K | Jun 29, 2023 |
| Praetorian Wealth Management, Inc. | 0.45% | 200,000 | 118.40K | Sep 29, 2023 |
| Wells Fargo & Company | 0.36% | 163,244 | 244.87K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.20% | 986,327 | 1.48M | Jun 29, 2023 |
| Global X Fds-The Global X Cannabis ETF | 2.08% | 934,512 | 553.23K | Sep 29, 2023 |
| Vanguard Extended Market Index Fund | 0.91% | 410,666 | 616.00K | Jun 29, 2023 |
| Cambria ETF Tr-Cambria Cannabis ETF | 0.38% | 171,570 | 101.57K | Sep 29, 2023 |
| Fidelity Extended Market Index Fund | 0.34% | 151,441 | 263.51K | May 30, 2023 |
| iShares Micro Cap ETF | 0.19% | 86,322 | 82.14K | Aug 30, 2023 |